T-cell immunosenescence emerges as a central driver in systemic lupus erythematosus (SLE), creating a self-perpetuating inflammatory cycle through mitochondrial dysfunction and senescence-associated secretory phenotype (SASP). These aged immune cells exhibit cell cycle arrest, dysregulated apoptosis, oxidative stress, and DNA damage that sustains chronic inflammation beyond traditional autoantibody mechanisms. The finding connects lupus pathology to broader aging biology, suggesting that what we consider an autoimmune disease may fundamentally be an accelerated immune aging disorder. This mechanistic understanding opens promising therapeutic avenues using senolytics like dasatinib, quercetin, and fisetin to eliminate senescent cells, or senomorphics like rapamycin and JAK inhibitors to suppress their inflammatory output. The approach represents a paradigm shift from symptom management toward targeting root cellular dysfunction. However, clinical translation faces significant challenges: determining optimal patient selection biomarkers, timing interventions appropriately, and managing potential immunosuppressive risks in already compromised patients. The cardiovascular and metabolic complications linked to T-cell senescence in lupus also suggest these therapies might address systemic manifestations beyond joint and skin symptoms, potentially improving overall healthspan in this patient population.